Tower Research Capital LLC TRC Reduces Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Tower Research Capital LLC TRC cut its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 54.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,796 shares of the company’s stock after selling 9,367 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Monte Rosa Therapeutics were worth $44,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in GLUE. TD Asset Management Inc grew its holdings in shares of Monte Rosa Therapeutics by 65.6% during the third quarter. TD Asset Management Inc now owns 193,168 shares of the company’s stock valued at $925,000 after buying an additional 76,550 shares during the last quarter. Corton Capital Inc. purchased a new stake in shares of Monte Rosa Therapeutics during the third quarter valued at $69,000. SG Americas Securities LLC purchased a new stake in shares of Monte Rosa Therapeutics during the third quarter valued at $66,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Monte Rosa Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 23,327 shares of the company’s stock valued at $132,000 after buying an additional 5,915 shares during the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Wedbush started coverage on shares of Monte Rosa Therapeutics in a report on Thursday, February 15th. They set an “outperform” rating and a $11.00 price objective on the stock.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE traded down $0.34 on Thursday, reaching $5.60. 176,102 shares of the company’s stock traded hands, compared to its average volume of 145,679. The firm has a market cap of $281.85 million, a price-to-earnings ratio of -2.06 and a beta of 1.54. The stock has a 50 day moving average price of $6.47 and a 200-day moving average price of $5.19. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $2.44 and a fifty-two week high of $8.84.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, March 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -2.25 EPS for the current fiscal year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.